References
- Khouzam RH. Chronic pain and its management in primary care. South Med J 2000;93:946-52; quiz 53
- The Mayday Fund Special Committee on Pain and the Practice of Medicine: a call to revolutionize chronic pain care in America: an opportunity in health care reform. Available at: http://www.maydaypainreport.org/report.php [Last accessed 22 September 2011]
- McCarberg B. Treatment of mild-to-moderate acute pain: what can we do to improve the standard of care? Am J Ther 2008;15(Suppl 10):S5-6
- Haanpaa ML, Backonja MM, Bennett MI, et al. Assessment of neuropathic pain in primary care. Am J Med 2009;122:S13-21
- National Centers for Health Statistics, Health, United States, 2006 Special Feature on Pain with Chartbook on Trends in the Health of Americans. Hyattsville, MD, USA. Available at: http://www.cdc.gov/nchs/data/hus/hus06.pdf [Last accessed 22 September 2011]
- Mantyselka P, Kumpusalo E, Ahonen R, et al. Pain as a reason to visit the doctor: a study in Finnish primary health care. Pain 2001;89:175-80
- Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA 1998;280:147-51
- Massachusetts Pain Initiative: Pain Survey Executive Summary. Available at: http://masspaininitiative.org/files/MassPI%20Pain%20Survey%20-%20Executive%20Summary%20v3.pdf [Last accessed 22 September 2011]
- Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443-54
- Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006;9:1-39
- Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007;23:648-60
- Katz NP, Adams EH, Benneyan JC, et al. Foundations of opioid risk management. Clin J Pain 2007;23:103-18
- Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 2007;297:249-51
- Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006;15:618-27
- Governale L. Outpatient prescription opioid utilization in the US, years 2000–2009. US Food and Drug Administration. 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM220950.pdf [Last accessed 22 September 2011]
- Gallagher RM, Rosenthal LJ. Chronic pain and opiates: balancing pain control and risks in long-term opioid treatment. Arch Phys Med Rehabil 2008;89:S77-82
- Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 2008;10:11-18
- Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs 2009;18:255-63
- Gagnon AM, Kahan M, Srivastava A. Opioid use and abuse: is there a problem? Clin J Pain 2007;23:661-2
- CARESAlliance: Building a Science of Patient Safety for Pain Management: Striking the Balance between Safety, Access, and Choice. Available at: http://www.caresalliance.org/Resources/C.A.R.E.S.%20Alliance%20White%20Paper%209-8-10%20Final.pdf [Last accessed 22 September 2011]
- Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. J Pain 2010;11:602-11
- Passik SD, Kirsh KL. The interface between pain and drug abuse and the evolution of strategies to optimize pain management while minimizing drug abuse. Exp Clin Psychopharmacol 2008;16:400-4
- Sullivan MD, Von Korff M, Banta-Green C, et al. Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain. Pain 2010;149:345-53
- McCarberg B, Stanos S. Key patient assessment tools and treatment strategies for pain management. Pain Pract 2008;8:423-32
- McLean SA, Clauw DJ, Abelson JL, et al. The development of persistent pain and psychological morbidity after motor vehicle collision: integrating the potential role of stress response systems into a biopsychosocial model. Psychosom Med 2005;67:783-90
- Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
- Sullivan MD, Edlund MJ, Fan MY, Woloshin S. Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 2008;138:440-9
- Caudill-Slosberg MA, Schwartz LM, et al. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain 2004;109:514-19
- Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain 2006;7:225-35
- Chou R. 2009 Clinical Guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain: what are the key messages for clinical practice? Pol Arch Med Wewn 2009;119:469-77
- Ashburn MA, Lipman AG. Pain in Society. In: Lipman AG (ed.) Pain Management for Primary Care Clinicians. Bethesda, MD: American Society of Health-System Pharmacists, 2004
- Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc 2009;84:593-601
- Chou R, Fanciullo GJ, Fine PG, et al. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10:131-46
- Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain 2008;24:497-508
- Passik SD, Hays L, Eisner N, et al. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother 2006;20:5-13
- Boscarino JA, Rukstalis M, Hoffman SN, et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 2010;105:1776-82
- Wasan AD, Butler SF, Budman SH, et al. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain 2007;23:307-15
- Smith HS, Kirsh KL, Passik SD. Chronic opioid therapy issues associated with opioid abuse potential. J Opioid Manag 2009;5:287-300
- Touchet BK, Yates WR, Coon KA. Opioid contract use is associated with physician training level and practice specialty. J Opioid Manag 2005;1:195-200
- U.S. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of national findings. September 2010. Available at: http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9ResultsP.pdf [Last accessed 22 September 2011]
- Substance Abuse and Mental Health Services Administration: Drug Abuse Warning Network (DAWN). Available at: http://www.samhsa.gov/data/DAWN.aspx [Last accessed 27 August 2012]
- Rocky Mountain Poison and Drug Center: The Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System. Available at: http://www.radars.org [Last accessed 22 September 2011]
- Partnership for a Drug-Free America: The Partnership Attitude Tracking Survey (PATS): Teens 2008 Report. Released February 26, 2009. Available at: http://www.drugfree.org/wp-content/uploads/2011/04/Full-Report-FINAL-PATS-Teens-2008_updated.pdf [Last accessed 1 August 2012]
- National Institute on Drug Abuse: Monitoring the Future: National Results on Adolescent Drug Use. Overview of Key Findings 2009. Available at: http://monitoringthefuture.org/pubs/monographs/overview2009 [Last accessed 23 September 2011]
- Boyd CJ, McCabe SE. Coming to terms with the nonmedical use of prescription medications. Subst Abuse Treat Prev Policy 2008;3:22
- Blazer DG, Wu LT. The epidemiology of substance use and disorders among middle aged and elderly community adults: national survey on drug use and health. Am J Geriatr Psychiatry 2009;17:237-45
- Grucza RA, Abbacchi AM, Przybeck TR, et al. Discrepancies in estimates of prevalence and correlates of substance use and disorders between two national surveys. Addiction 2007;102:623-9
- Spiller H, Lorenz DJ, Bailey EJ, et al. Epidemiological trends in abuse and misuse of prescription opioids. J Addict Dis 2009;28:130-6
- The National Center on Addiction and Substance Abuse at Columbia University. Under the counter: the diversion and abuse of controlled prescription drugs in the U.S. July 2005. Available at: www.casacolumbia.org/download.aspx?path=/UploadedFiles/tt3bl4lk.pdf [Last accessed 23 September 2011]
- Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008;11:S63-88
- Inciardi JA, Surratt HL, Kurtz SP, et al. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med 2007;8:171-83
- Denisco RA, Chandler RK, Compton WM. Addressing the intersecting problems of opioid misuse and chronic pain treatment. Exp Clin Psychopharmacol 2008;16:417-28
- Centers for Disease Control and Prevention. Adult use of prescription opioid pain medications – Utah. MMWR Morb Mortal Wkly Rep 2010;59:153-7
- Ponte CD, Johnson-Tribino J. Attitudes and knowledge about pain: an assessment of West Virginia family physicians. Fam Med 2005;37:477-80
- National Institute on Drug Abuse: Prescription Drug Abuse and Addiction. Available at: http://www.nida.nih.gov/PDF/RRPrescription.pdf [Last accessed 23 September 2011]
- Potter M, Schafer S, Gonzalez-Mendez E, et al. Opioids for chronic nonmalignant pain. Attitudes and practices of primary care physicians in the UCSF/Stanford Collaborative Research Network. University of California, San Francisco. J Fam Pract 2001;50:145-51
- Morley-Forster PK, Clark AJ, Speechley M, et al. Attitudes toward opioid use for chronic pain: a Canadian physician survey. Pain Res Manag 2003;8:189-94
- Nwokeji ED, Rascati KL, Brown CM, et al. Influences of attitudes on family physicians’ willingness to prescribe long-acting opioid analgesics for patients with chronic nonmalignant pain. Clin Ther 2007;29(Suppl):2589-602
- Gooberman-Hill R, Heathcote C, Reid CM, et al. Professional experience guides opioid prescribing for chronic joint pain in primary care. Fam Pract 2010;28:102-9
- Wright C 4th, Schnoll S, Bernstein D. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective. Ann N Y Acad Sci 2008;1141:284-303
- Dart RC, Dasgupta N, Bailey E, et al. Evaluation of risk evaluation and mitigation strategy (REMS) programs: comments for Docket No. FDA-2009-N-0143, Available at: http://www.radars.org/Portals/1/RADARS(R)%20System_Comments%20Docket%20No%20%20FDA-2009-N-0143_08JUL2010.pdf [Last accessed 27 August 2012]
- U.S. Food and Drug Administration. Opioid Drugs and Risk Evaluation and Mitigation Strategies (REMS). Available at: http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm163647.htm [Last accessed 9 July 2012]
- U.S. Food and Drug Administration. Remarks at the Office of National Drug Control Policy Announcement of the Prescription Drug Abuse Action Plan [as delivered by Margaret A. Hamburg, MD, Commissioner of Food and Drugs]. April 19, 2011. Available at: http://www.fda.gov/NewsEvents/Speeches/ucm254856.htm [Last accessed 23 September 2011]
- U.S. Food and Drug Administration. NDA 021306: Butrans (buprenorphine) transdermal system: partial opioid agonist. Risk evaluation and mitigation strategy (REMS). Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM220880.pdf [Last accessed 23 September 2011]
- U.S. Food and Drug Administration. NDA 22-272: OxyContin (oxycodone hydrochloride controlled-release) tablets: opioid agonist. Risk evaluation and mitigation strategy (REMS). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022272s000remsOxycontin.pdf [Last accessed 23 September 2011]
- U.S. Food and Drug Administration. NDA 22-321: Embeda (morphine sulfate and naltrexone HCl) extended-release capsules. Risk evaluation and mitigation strategy (REMS). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022321s000REMS.pdf [Last accessed 23 September 2011]
- U.S. Food and Drug Administration. NDA 22-266: Onsolis (fentanyl buccal soluble film): opioid analgesic. Risk evaluation and mitigation strategy (REMS). Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187537.pdf [Last accessed 23 September 2011]
- Hays LR. A profile of OxyContin addiction. J Addict Dis 2004;23:1-9
- Marsch LA, Bickel WK, Badger GJ, et al. Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 2001;299:1056-65
- Roset PN, Farre M, de la Torre R, et al. Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males. Drug Alcohol Depend 2001;64:285-98
- Budman SH, Grimes Serrano JM, Butler SF. Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduct J 2009;6:8
- Inciardi JA, Surratt HL, Cicero TJ, et al. Prescription opioid abuse and diversion in an urban community: the results of an ultrarapid assessment. Pain Med 2009;10:537-48
- Inciardi JA, Surratt HL, Cicero TJ, et al. The ‘black box’ of prescription drug diversion. J Addict Dis 2009;28:332-47
- Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse? CNS Drugs 2010;24:805-10
- U.S. Department of Health and Human Services. Food and Drug Administration. Guidance for Industry: Assessment of Abuse Potential of Drugs. Draft Guidance. January 2010. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf [Last accessed 6 January 2012]
- Lahmeyer HW, Craig RJ. Pentazocine–naloxone: another ‘addiction-proof’ drug of abuse. Int J Addict 1987;22:1163-6
- Lahmeyer HW, Craig RJ. Pentazocine–naloxone: an ‘abuse proof’ drug can be abused. J Clin Psychopharmacol 1986;6:389-90
- Reed DA, Schnoll SH. Abuse of pentazocine–naloxone combination. JAMA 1986;256:2562-4
- FDA Approves EXALGO (Hydromorphone HCL) Extended-Release Tablets. March 2, 2010. Available at: http://investor.covidien.com/phoenix.zhtml?c=207592&p=irol-newsArticle&ID=1397337 [Last accessed 23 September 2011]
- Exalgo [package insert]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals Inc., Covidien. November, 2010. Available at: http://www.exalgo.com/media/pdf/EXALGO_FullPrescribingInformation.pdf [Last accessed 26 September 2011]
- Brennan MJ, Stanos S. Strategies to optimize pain management with opioids while minimizing risk of abuse. PM R 2010;2:544-58
- Purdue Pharma LP receives FDA Approval for Butrans (buprenorphine) Transdermal System CIII. July 1, 2010. Available at: http://www.purduepharma.com/news-media/2010/07/purdue-pharma-l-p-receives-fda-approval-for-butrans-buprenorphine-transdermal-system-ciii/ [Last accessed 27 August 2012]
- Butrans [package insert]. Stamford, CT: Purdue Pharma LP, June, 2010. Available at: http://www.purduepharma.com/pi/prescription/butranspi.pdf [Last accessed 23 September 2011]
- Endo Announces FDA Approval of a New Formulation of Opana ER Designed to be Crush-Resistant. December 12, 2011. Available at: http://www.endo.com/news-events/press-releases [Last accessed 27 August 2012]
- Oxycontin [package insert]. Stamford, CT: Purdue Pharma LP, 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022272s006lbl.pdf [Last accessed 23 September 2011]
- Statement of Purdue Pharma LP Regarding FDA's Approval of Reformulated OxyContin (oxycodone HCL controlled-release) tablets. April 5, 2010. Available at: http://www.purduepharma.com/news-media/2010/04/statement-of-purdue-pharma-l-p-regarding-fdas-approval-of-reformulated-oxycontin-oxycodone-hcl-controlled-release-tablets/ [Last accessed 27 August 2012]
- Oxecta [package insert]. Bristol, TN, USA: King Pharmaceuticals, Inc., June, 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202080s000lbl.pdf [Last accessed 26 September 2011]
- Acura Pharmaceuticals Inc. Aversion Technology. Available at: http://acurapharm.com/research-development/aversion-technology/ [Last accessed 6 January 2012]
- Rolleri RL, Faulknor JY, Schoedel KA, et al. Intranasal abuse potential of immediate-release oxycodone HCl formulated to deter intranasal abuse (IRO-A). Presented at: 73rd Annual Meeting of The College on Problems of Drug Dependence, 18–23 June 2011, Hollywood, FL, USA
- FDA Approves Embeda for Management of Moderate to Severe Chronic Pain. August 13, 2009. Available at: http://www.drugs.com/newdrugs/fda-approves-embeda-management-moderate-severe-chronic-pain-1557.html [Last accessed 23 September 2011]
- EMBEDA [package insert]. Bristol, TN, USA: King Pharmaceuticals, Inc., July, 2012, Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=694 [Last accessed 27 August 2012]
- Young AM, Havens JR, Leukefeld CG. Route of administration for illicit prescription opioids: a comparison of rural and urban drug users. Harm Reduct J 2010;7:24
- McCabe SE, Cranford JA, Boyd CJ, et al. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav 2007;32:562-75
- Collegium Pharmaceutical Inc. Receives FDA Fast Track Designation for Tamper Resistant, Chronic Pain Product, COL-172. June 10, 2010. Available at: http://collegiumpharma.com/press-releases/43-june-10-2010–collegium-pharmaceutical-inc-receives-fda-fast-track-designation-for-tamper-resistant-chronic-pain-product-col-172 [Last accessed 23 September 2011]
- Collegium Pharmaceutical Inc. Announces Submission of a Request for Special Protocol Assessment to FDA for Pivotal Trial for Tamper Resistant, Extended Release Opioid (COL-003). June 10, 2009. Available at: http://www.businesswire.com/news/home/20090610005046/en/Collegium-Pharmaceutical-Announces-Submission-Request-Special-Protocol [Last accessed 23 September 2011]
- Egalet Ltd. Profile & Pipeline. Available at: http://www.egalet.com/index.dsp?area=5 [Last accessed 23 September 2011]
- Friedmann N, Klutzaritz V, Webster L. Long-term safety of Remoxy (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain. Pain Med 2011;12:755-60
- Friedmann N, Klutzaritz V, Webster L. Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. J Opioid Manag 2011;7:193-202
- Intellipharmaceutics. The Future of Drug Delivery, Products: Rexista (Oxycodone). Available at: http://www.intellipharmaceutics.com/oxycodone.cfm [Last accessed 23 September 2011]
- Intellipharmaceutics Announces Significant Advance in its Abuse-deterrent Oxycodone Program. May 20, 2010. Available at: http://www.intellipharmaceutics.com/releasedetail.cfm?ReleaseID=472169 [Last accessed 27 August 2012]
- ELI-216. Elite Pharmaceuticals Inc. Product Pipeline and Commercial Products. Available at: http://elitepharma.com/product_pipeline.asp [Last accessed 23 September 2011]